港股异动 | 中国生物制药(01177)涨超4% 旗下正大晴天自研HER2双抗ADC新辅助治疗乳腺癌取得重要突破

智通财经
Nov 26

智通财经APP获悉,中国生物制药(01177)涨超4%,截至发稿,涨2.87%,报7.16港元,成交额1.74亿港元。

消息面上,11月25日,注射用TQB2102单药用于HER2阳性乳腺癌新辅助治疗的Ⅱ期临床研究结果,获国际著名期刊《临床肿瘤学杂志》(Journal of Clinical Oncology,IF 43.4) 在线发表。TQB2102是中国生物制药旗下正大天晴自主研发的一种靶向HER2两个非重叠表位ECD2及ECD4的抗体偶联药物(ADC)。该项研究由复旦大学附属肿瘤医院邵志敏教授团队领衔,为首个证实双表位HER2 ADC TQB2102在乳腺癌新辅助治疗阶段具有良好疗效和安全性的研究,Ⅲ期注册临床研究正在开展中。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10